A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Summary

The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure of primary response to, or have demonstrated disease progression while on ruxolitinib.

Timeline

Start

2012-05-22

Primary completion

2015-03-20

Completion

2026-12

Drugs

Indications